Journal of Clinical Endocrinology & Metabolism, Vol 78, 423-427, Copyright © 1994 by Endocrine Society

ARTICLES

Serum interleukin-6 in amiodarone-induced thyrotoxicosis

L Bartalena, L Grasso, S Brogioni, F Aghini-Lombardi, LE Braverman and E Martino
Istituto di Endocrinologia, University of Pisa, Tirrenia-Pisa, Italy.

Amiodarone, an iodine-rich cardiac drug, may induce thyrotoxicosis (AIT), which can occur in patients with preexisting thyroid abnormalities and in subjects with apparently normal thyroid glands. The pathogenesis of AIT is often due to iodine-induced excessive thyroid hormone synthesis, especially in patients with underlying thyroid disease. In some instances, however, AIT may be related to a destructive process due to amiodarone-induced thyroiditis, resulting in thyroid cell damage and thyroid hormone release into the circulation. Another thyroid inflammatory process, subacute thyroiditis, has been recently reported to be associated with markedly increased serum interleukin-6 (IL-6) levels. To investigate the significance of serum IL-6 levels in AIT, we evaluated in a cross-sectional study the following subjects: 27 AIT patients, 15 with no apparent thyroid abnormalities (AIT-) and 12 with nodular goiter and/or thyroid autoimmune disease (AIT+); 14 euthyroid patients receiving chronic amiodarone therapy; 10 patients with amiodarone-induced hypothyroidism; 56 patients with spontaneous hyperthyroidism due to Graves' disease (n = 35) or toxic adenoma/nodular goiter (n = 21); 20 subjects with nontoxic goiter; and 50 healthy controls. Serum free thyroid hormone concentrations did not differ in patients with amiodarone-induced or spontaneous hyperthyroidism. Mean (+/- SE) serum IL-6 values were as follows: AIT-, 573.5 +/- 78.7 fmol/L (range, 149.4-1145.1); AIT+, 152.7 +/- 46.3 fmol/L (range, < 25-505.6); euthyroid patients receiving chronic amiodarone therapy, 51.4 +/- 10.0 fmol/L (range, < 25-122.5); amiodarone-induced hypothyroidism, 43.8 +/- 8.4 fmol/L (range, < 25- 84.3); Graves' disease, 108.2 +/- 18.2 fmol/L (range, < 25-250); toxic adenoma/nodular goiter, 97.6 +/- 10.3 fmol/L (range, < 25-168.9); nontoxic goiter, 47.3 +/- 7.1 fmol/L (range, < 25-106.6); and controls, 37.8 +/- 6.2 fmol/L (range, < 25-99.4). Serum IL-6 values in AIT- patients were markedly higher (P < 0.0001) than those in all other groups. Values in AIT+, although slightly higher, did not significantly differ from those in patients with spontaneous hyperthyroidism. AIT- patients had low 24-h thyroidal radioiodine uptake (RAIU), whereas AIT+ had inappropriately low normal to high (9-58%) RAIU values in the presence of excess iodine. The presence of markedly elevated serum IL-6 concentrations and low thyroidal RAIU values in patients with AIT without underlying thyroid disease suggests the presence of amiodarone- induced thyroiditis as the etiology of thyrotoxicosis. Treatment of 2 such patients with prednisone was associated with a dramatic reduction and prompt normalization of IL-6 and thyroid hormone values.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				D. Conen, L. Melly, C. Kaufmann, S. Bilz, P. Ammann, B. Schaer, C. Sticherling, B. Muller, and S. Osswald Amiodarone-Induced Thyrotoxicosis: Clinical Course and Predictors of Outcome J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2350 - 2355. [Abstract] [Full Text] [PDF]

				A. J O'Sullivan, M. Lewis, and T. Diamond Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur. J. Endocrinol., April 1, 2006; 154(4): 533 - 536. [Abstract] [Full Text] [PDF]

				E. N. Pearce, A. P. Farwell, and L. E. Braverman Thyroiditis N. Engl. J. Med., June 26, 2003; 348(26): 2646 - 2655. [Full Text] [PDF]

				E. Algun, S. Alici, C. Topal, S. Ugras, R. Erkoc, M. E. Sakarya, and N. Ozbey Coexistence of subacute thyroiditis and renal cell carcinoma: a paraneoplastic syndrome Can. Med. Assoc. J., April 15, 2003; 168(8): 985 - 986. [Abstract] [Full Text] [PDF]

				F. Osman, J. A. Franklyn, M. C. Sheppard, and M. D. Gammage Successful Treatment of Amiodarone-Induced Thyrotoxicosis Circulation, March 19, 2002; 105(11): 1275 - 1277. [Abstract] [Full Text] [PDF]

				E. Martino, L. Bartalena, F. Bogazzi, and L. E. Braverman The Effects of Amiodarone on the Thyroid Endocr. Rev., April 1, 2001; 22(2): 240 - 254. [Abstract] [Full Text]

				G. H. Daniels Amiodarone-Induced Thyrotoxicosis J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 3 - 8. [Full Text]

				T. Di Matola, F. D’Ascoli, G. Fenzi, G. Rossi, E. Martino, F. Bogazzi, and M. Vitale Amiodarone Induces Cytochrome c Release and Apoptosis through an Iodine-Independent Mechanism J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4323 - 4330. [Abstract] [Full Text]

				K.-C. Loh Current concepts in medicine: Amiodarone-induced thyroid disorders: a clinical review Postgrad. Med. J., March 1, 2000; 76(893): 133 - 140. [Abstract] [Full Text]

				M. Vitale, T. Di Matola, F. D'Ascoli, S. Salzano, F. Bogazzi, G. Fenzi, E. Martino, and G. Rossi Iodide Excess Induces Apoptosis in Thyroid Cells through a p53-Independent Mechanism Involving Oxidative Stress Endocrinology, February 1, 2000; 141(2): 598 - 605. [Abstract] [Full Text] [PDF]

				C M Newman, A Price, D W Davies, T A Gray, and A P Weetman Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy Heart, February 1, 1998; 79(2): 121 - 127. [Full Text]

				P. Lakatos, J. Foldes, C. Horvath, L. Kiss, A. Tatrai, I. Takacs, G. Tarjan, and P. H. Stern Serum Interleukin-6 and Bone Metabolism in Patients with Thyroid Function Disorders J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 78 - 81. [Abstract] [Full Text] [PDF]

				M. I. Surks and R. Sievert Drugs and Thyroid Function N. Engl. J. Med., December 21, 1995; 333(25): 1688 - 1694. [Full Text] [PDF]